Laetrile B17 Amygdalin / CAIX/CA9 Cancer Research Results

Laetrile / Amygdalin — Amygdalin is a naturally occurring cyanogenic diglucoside concentrated in bitter apricot kernels and other Prunus seeds; it can be enzymatically hydrolyzed to prunasin, benzaldehyde, glucose, and hydrogen cyanide. Amygdalin is commonly abbreviated AMY or AMG. “Laetrile” has historically referred to purified or semisynthetic cyanogenic preparations related to amygdalin and should not be treated as chemically synonymous in all contexts. “Vitamin B17” is a nonrecognized marketing designation and amygdalin is not a vitamin. It is best classified as a plant-derived cyanogenic natural product with experimental anticancer activity but substantial cyanide-toxicity liability. Neither amygdalin, Laetrile, nor “vitamin B17” is authorized by Health Canada as a cancer treatment, and Laetrile is not FDA-approved.

Primary mechanisms (ranked):

1. Cyanogenic hydrolysis and hydrogen-cyanide generation: microbial or enzymatic β-glucosidase-mediated cleavage can release HCN, which inhibits mitochondrial cytochrome-c oxidase and cellular respiration. This mechanism is cytotoxic but has not been demonstrated to be selectively activated in human tumors.
2. Intrinsic apoptosis: experimental cancer models report ↑ BAX, ↓ BCL-2 and ↑ caspase-3 activity, shifting the mitochondrial apoptotic balance toward cell death.
3. Cell-cycle and proliferation suppression: ↓ CDK1 and cyclin B and context-dependent alterations in other cyclins/CDKs can produce G0/G1, G1, S or G2 arrest depending on cancer model.
4. AKT/mTOR and adhesion/invasion signaling: experimental studies report ↓ AKT-mTOR activity, altered integrin/cadherin signaling and reduced clonogenic growth, adhesion or migration.
5. Metabolic tumor targets: recent cervical-cancer studies identify CA9 and HK2 as candidate amygdalin-sensitive targets associated with altered glycolytic and metabolic signaling; this remains preclinical.
6. Proteostasis: inhibition of 20S/26S proteasome activity has been reported in breast-cancer cells and may contribute to proteotoxic stress and apoptosis.

Bioavailability / PK relevance: Oral parent-amygdalin bioavailability is very low and highly dependent on gastrointestinal microbiota. In human pharmacokinetic studies, a 500-mg oral dose produced parent-drug plasma concentrations below approximately 0.525 µg/mL while substantially increasing blood cyanide; by contrast, intravenous dosing produced plasma amygdalin concentrations exceeding 1,000 µg/mL with much less immediate cyanide formation. Intravenous amygdalin showed an elimination half-life of approximately 2 hours. Oral exposure is therefore dominated by gut-dependent metabolism and carries substantially greater cyanide risk. Raw apricot kernels, other β-glucosidase-containing foods, and high-dose vitamin C may further increase toxicity.

In-vitro vs systemic exposure relevance: Common anticancer experiments often use approximately 1–10 mg/mL amygdalin, with several mechanistic studies using 10 mg/mL. These concentrations are orders of magnitude above the approximately 0.0005 mg/mL peak parent-amygdalin concentration reported after a 500-mg oral human dose. Consequently, direct parent-compound effects observed at millimolar in-vitro concentrations cannot be assumed to occur after conventional oral exposure. Oral administration instead creates a separate pharmacology dominated by local microbial conversion to cyanide, making simple concentration extrapolation particularly unreliable.

Clinical evidence status: Preclinical with negative human efficacy evidence. Multiple cell-culture studies demonstrate antiproliferative and pro-apoptotic activity, and mechanistic work continues, including recent CA9/HK2 findings. However, no randomized controlled trial has established anticancer efficacy. The principal prospective clinical study involving 178 cancer patients found no substantive benefit in tumor response, symptoms or survival and documented cyanide toxicity. Systematic reviews have concluded that the benefit-risk balance for Laetrile/amygdalin as a cancer treatment is negative. It should not be classified as an established anticancer therapy or adjunct.

Mechanistic Profile